Investing.com - Financial Markets Worldwide

Erytech Pharma (ERYP)

Symbol
Exchange
Currency
ERYP
ParisEURReal-time
ERYP
NASDAQUSDReal-time
0.8460
+0.0140(+1.68%)
-Closed.
Currency in EUR
  • Volume:
    73,871
  • Bid/Ask:
    0.0000/0.0000
  • Day's Range:
    0.8020 - 0.8460

ERYP Overview

Prev. Close
0.832
Day's Range
0.802-0.846
Revenue
6.64M
Open
0.82
52 wk Range
0.285-1.479
EPS
-0.007
Volume
73,871
Market Cap
28.83M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
257,002
P/E Ratio
-131.43
Beta
2.25
1-Year Change
-28.55%
Shares Outstanding
34,117,798
Next Earnings Date
Sep 11, 2023
What is your sentiment on Erytech Pharma?
or
Market is currently closed. Voting is open during market hours.

Erytech Pharma Analysis

Erytech Pharma Company Profile

Erytech Pharma Company Profile

Industry
Biotechnology & Medical Research
Sector
Healthcare
Employees
149
Market
France
  • Type:Equity
  • Market:France
  • ISIN:FR0011471135

Erytech Pharma SA, also known as ERYTECH Pharma, is a France-based biopharmaceutical company developing medicinal products mainly in oncology, hematology and immunology fields of business. The Company offers ESY-ASP (GRASPA), a medicinal product consisting of L-Asparaginase entrapped into human homologous red blood cells. The product is used for treatment of Acute Lymphoblastic Leukemia (ALL), a childhood cancer. The Company's technology is based on the use of human red blood cells (RBCs) to improve the pharmacokinetic (PK) and pharmacodynamic (PD) properties of therapeutic enzymes, for instance asparaginase. The enzyme can destroy asparagine and deprive cancer cells of an important nutrient for these cells, resulting in their death.

Read More

Income Statement

Analyst Price Target

Average3.6000 (+325.5319% Upside)
High3.6000
Low3.6000
Price0.8460
No. of Analysts1
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Analysts Consensus

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuyNeutralSellStrong SellSell
Technical IndicatorsStrong BuyStrong BuyBuyStrong SellSell
SummaryStrong BuyBuyNeutralStrong SellSell

Trending Stocks

Trending Stocks

Name
Last
High
Low
Chg.
Chg. %
Vol.
Time
Walt Disney
92.5293.0891.86+0.36+0.39%11.01MNYSE
ZALANDO ADR
13.2313.4913.19-0.38-2.79%24.85KOTC Markets
Lowe’s
211.21211.85208.00+4.05+1.96%3.27MNYSE
MGM Growth Properties
41.6442.2840.330.000.00%0.00NYSE
Brightspire Capital
6.566.596.42+0.130+2.02%925.20KNYSE
ACELYRIN
16.9717.5916.60-0.13-0.76%367.76KNASDAQ
Casi Pharma
2.452.562.35-0.1526-5.86%27.55KNASDAQ
Spotify Tech
148.31155.68147.54-4.72-3.08%1.55MNYSE
ServisFirst Bancshares
46.1047.1345.38+0.92+2.04%419.95KNYSE
Allena Pharma
0.00020.00020.00020.000.00%15.19KOTC Markets
Roku
68.0372.5264.75+5.05+8.02%23.35MNASDAQ
Arco Platform 
12.1412.5311.95-0.27-2.18%46.30KNASDAQ
Globalstar Inc
1.261.281.215+0.0200+1.61%4.75MNYSE
Stitch Fix
4.715.124.13+1.03+27.99%24.34MNASDAQ
Virtus Global
6.176.2396.16-0.020-0.32%411.96KNYSE
  • WEBINAR ON ERYASPASE IN PANCREATIC CANCER (SEPTEMBER 1, 2021)ERYTECH TO PARTICIPATE IN THE CITI 16TH ANNUAL BIOPHARMA CONFERENCE(September 8 2021 through September 10, 2021)ERYTECH HOSTING KEY OPINION LEADER WEBINAR ON ERYASPASE IN PANCREATIC CANCERERYTECH Hosting Key Opinion Leader Webinar on Eryaspase in Pancreatic Cancer(September 1 2021)ERYTECH GRANTED U.S. FDA FAST TRACK DESIGNATION FOR ERYASPASE IN HYPERSENSITIVE ALL(July 29, 2021)Erytech is starting the push for sales, fda approval by the end of the month if not sooner. After fda approval eryteck will hit the ceiling.
    0